TAG-72 CAR-T cells

TAG-72 CAR-T cells are **genetically engineered T cells** expressing a chimeric antigen receptor (CAR) that specifically targets **tumor-associated glycoprotein 72 (TAG-72)**, a cell surface antigen overexpressed in several solid tumors, notably ovarian and colorectal cancers. The CAR construct commonly utilizes a **humanized anti-TAG72 single-chain variable fragment (scFv)** to directly recognize TAG-72, and incorporates an intracellular co-stimulatory signaling domain, such as **4-1BB**, to enhance persistence, cytokine production (like IFNγ and IL-2), and anti-tumor efficacy. TAG-72 CAR-T cell therapy is being evaluated primarily for **epithelial ovarian cancer**, with ongoing phase I trials examining safety, tolerability, and anti-tumor activity. Administration by **intraperitoneal infusion**, rather than intravenous, is associated with greater tumor control and extended survival in preclinical models. Developers have demonstrated potent and highly selective killing of TAG-72-positive tumor cells both in vitro and in vivo, with the potential for broader application to multiple solid tumor types expressing TAG-72[1][2].

Brand names

TAG-72 CAR-T cellsTAG72 CAR-T cellsTAG 72 CAR-T cells

Other names

TAG-72 chimeric antigen receptor T cellsTAG72 chimeric antigen receptor T cellsTAG 72 chimeric antigen receptor T cells